MabVax Therapeutics Story Overview

MBVX -- USA Stock  

USD 1.36  0.41  23.16%

Macroaxis does not monitor all media channels or aggregates social signals for MabVax Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on MabVax Therapeutics, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for MabVax Therapeutics. Please see also MabVax Therapeutics Hype Analysis, MabVax Therapeutics Correlation and MabVax Therapeutics Performance.
Mabvax Therapeutics Holdings Inc Stock Price Performance in Focus
The Business UnionStock-research Ratings MabVax Therapeutics Holdings, Inc. , Digital Ally, Inc. Analyst JournalFull coverage

Read More...   

Story Momentum

This media report from earlebusinessunion.com distributed on December 7, 2017 was a factor to the next trading day price decrease.The trading delta at closing time against the next closing price was 1.52% . The trading delta at closing time when the story was published against the current closing price is 91.42% .

Similar stores for MabVax Therapeutics

Influential Analyst Rating Changes Helios and Matheson Analytics Inc. , MabVax Therapeutics Holdings, Inc ...news
Analyst JournalFull coverage
few days ago at http://prommanews.com 
MabVax Therapeutics Holdings, Inc. Is At 1.50 Formed Wedge Guggenheim Credit Allocation Fund GGM ...
news
Promma NewsFull coverage
over three weeks ago at http://mostvolatilestocks.com 
Eye Catching Stock for Investors MabVax Therapeutics Holdings, Inc.
news
MostVolatileStocks Full coverage
over three weeks ago at http://www.thestreetpoint.com 
How To Take Control on Your business through These- Chesapeake Granite Wash Trust , MabVax ...
Thestreet News
The Stock Street Full coverage
over a month ago at http://simplywall.st 
Is MabVax Therapeutics Holdings Incs CEO Being Overpaid
news
Simply Wall StFull coverage
over a month ago at www.macroaxis.com 
Sale by Wick Michael M of 500 shares of MabVax Therapeutics
Macroaxis News
Filed transaction by Mabvax Therapeutics Holdi director. General open market or private sale of non-derivative or derivative security
over a month ago at www.macroaxis.com 
Exercise or conversion by Thomas Varvaro of 513 shares of MabVax Therapeutics subject to Rule 16b-3
Macroaxis News
Filed transaction by Mabvax Therapeutics Holdi director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at http://www.bibeypost.com 
EPS for Bunge Limited Expected At 0.34 Mabvax Therapeutics Holdings SI Increased By 12.25
news
Bibeypost.comFull coverage
over two months ago at http://thewellesleysnews.com 
Stock-research Ratings MabVax Therapeutics Holdings, Inc. , SMART Global Holdings, Inc.
news
Analyst JournalFull coverage
over two months ago at www.macroaxis.com 
Sale by Wick Michael M of 800 shares of MabVax Therapeutics
Macroaxis News
Filed transaction by Mabvax Therapeutics Holdi director. General open market or private sale of non-derivative or derivative security
over three months ago at www.macroaxis.com 
Acquisition by Gregory Hanson of 1087 shares of MabVax Therapeutics subject to Rule 16b-3
Macroaxis News
Filed transaction by Mabvax Therapeutics Holdi officer. Grant, award or other acquisition pursuant to Rule 16b-3
over three months ago at http://postanalyst.com 
The Biggest 3 Holders Of MabVax Therapeutics Holdings, Inc.
news
MabVax Therapeutics Holdings, Inc. is on recovery track with 117.78 percent gain from a 1-year low price of 0.43. The company added 14.8 percent to attain the price of 0.93 on 12072017. Investors Putting MabVax Therapeutics Holdings, Inc. Under the ... - Nelson Research Investors are Watching Technical Levels on Shares of Mabvax Therapeutics ... - Hayden Business Journal

Did you try this?

Run Aroon Oscillator Now
   

Aroon Oscillator

Analyze current equity momentum using Aroon Oscillator and other momentum ratios
All  Next Launch Aroon Oscillator

Beta

Beta Comparative Analysis
  Beta 
      MabVax Therapeutics Comparables 
MabVax Therapeutics is currently under evaluation in beta category among related companies. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of financial instrument to the financial market in which this instrument is traded. For example if Beta of equity is 2, it will be expected to significantly outperform market when market is going up and significantly underperform when market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns during over time.

Peers

MabVax Therapeutics Related Equities
VCEL  1.74 %   
0%
13.0%
DRNA  1.31 %   
0%
9.0%
DRRX  0.52 %   
0%
3.0%
DMTX  0.00 %   
0%
0%
DNLI  0.05 %   
1.0%
0%
DMPI  1.01 %   
7.0%
0%
NK  1.76 %   
13.0%
0%
VBIV  2.01 %   
15.0%
0%
VBLT  2.27 %   
17.0%
0%
DOVA  13.18 %   
100.0%
0%
Please see also MabVax Therapeutics Hype Analysis, MabVax Therapeutics Correlation and MabVax Therapeutics Performance. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.